Citadel Advisors
ARRY

Citadel Advisors’s Array Biopharma Inc ARRY Stock Holding History

Citadel Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-295,800
Closed -$13.7M – 10177
2019
Q2 		$13.7M Buy
295,800
+14,500
+5% +$407K 0.01% 1798
2019
Q1 		$6.86M Buy
281,300
+75,000
+36% +$1.56M ﹤0.01% 2548
2018
Q4 		$2.94M Sell
206,300
-11,800
-5% -$179K ﹤0.01% 3545
2018
Q3 		$3.31M Sell
218,100
-7,200
-3% -$110K ﹤0.01% 3572
2018
Q2 		$3.78M Buy
225,300
+105,500
+88% +$1.68M ﹤0.01% 3152
2018
Q1 		$1.96M Buy
119,800
+12,900
+12% +$207K ﹤0.01% 3775
2017
Q4 		$1.37M Sell
106,900
-6,400
-6% -$72.8K ﹤0.01% 4176
2017
Q3 		$1.39M Buy
113,300
+68,800
+155% +$639K ﹤0.01% 3865
2017
Q2 		$372K Sell
44,500
-8,900
-17% -$72.8K ﹤0.01% 5556
2017
Q1 		$477K Sell
53,400
-57,100
-52% -$608K ﹤0.01% 5110
2016
Q4 		$971K Sell
110,500
-27,000
-20% -$199K ﹤0.01% 3893
2016
Q3 		$928K Buy
137,500
+100,400
+271% +$388K ﹤0.01% 3928
2016
Q2 		$132K Sell
37,100
-54,800
-60% -$179K ﹤0.01% 6076
2016
Q1 		$271K Buy
91,900
+51,800
+129% +$155K ﹤0.01% 5229
2015
Q4 		$169K Sell
40,100
-8,400
-17% -$38.3K ﹤0.01% 6020
2015
Q3 		$221K Buy
48,500
+13,600
+39% +$80.6K ﹤0.01% 6014
2015
Q2 		$252K Buy
34,900
+12,900
+59% +$95.2K ﹤0.01% 6009
2015
Q1 		$162K Buy
22,000
+5,400
+33% +$38.4K ﹤0.01% 6409
2014
Q4 		$79K Buy
16,600
+6,000
+57% +$23.7K ﹤0.01% 6852
2014
Q3 		$38K Sell
10,600
-9,200
-46% -$36.3K ﹤0.01% 7091
2014
Q2 		$90K Buy
19,800
+8,200
+71% +$33.9K ﹤0.01% 6314
2014
Q1 		$55K Sell
11,600
-2,400
-17% -$12.1K ﹤0.01% 6705
2013
Q4 		$70K Buy
+14,000
New +$76.2K ﹤0.01% 5859

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Citadel Advisors's ARRY Position: Q3 2019 in Review

Citadel Advisors sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 4,346,050 shares — an estimated $201M sold.

Citadel Advisors first reported a position in ARRY in Q2 2013 and held it in 24 quarters. The position peaked at $201M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Citadel Advisors reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Citadel Advisors sold 4,346,050 Array Biopharma Inc shares in Q3 2019, an estimated $201M.
  • Citadel Advisors first reported a position in Array Biopharma Inc in Q2 2013 and held it in 24 quarters.
  • Citadel Advisors's Array Biopharma Inc position peaked at $201M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.